Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) CEO Howard Robin sold 418 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total value of $30,087.64. Following the transaction, the chief executive officer owned 54,627 shares of the company’s stock, valued at $3,932,051.46. The trade was a 0.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Nektar Therapeutics Stock Performance
Shares of NKTR opened at $74.02 on Friday. The business has a 50-day moving average of $69.63 and a 200 day moving average of $70.36. Nektar Therapeutics has a fifty-two week low of $26.45 and a fifty-two week high of $109.00. The firm has a market cap of $2.53 billion, a P/E ratio of -11.05 and a beta of 1.14.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($1.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.74. The firm had revenue of $10.13 million during the quarter, compared to analyst estimates of $10.43 million. Nektar Therapeutics had a negative net margin of 287.84% and a negative return on equity of 37.87%. As a group, research analysts predict that Nektar Therapeutics will post -8.6 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Nektar Therapeutics
Analyst Ratings Changes
Several equities research analysts have issued reports on the company. Canaccord Genuity Group began coverage on Nektar Therapeutics in a research report on Wednesday, July 22nd. They set a “buy” rating and a $153.00 target price on the stock. Piper Sandler increased their price objective on Nektar Therapeutics from $105.00 to $192.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. JPMorgan Chase & Co. assumed coverage on Nektar Therapeutics in a research note on Friday. They issued a “neutral” rating and a $65.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nektar Therapeutics in a research report on Tuesday, June 2nd. Finally, Wall Street Zen raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $141.50.
View Our Latest Stock Analysis on Nektar Therapeutics
Nektar Therapeutics News Summary
Here are the key news stories impacting Nektar Therapeutics this week:
- Positive Sentiment: Nektar’s latest quarterly results included an adjusted loss of $1.23 per share, substantially better than the $1.97 analyst consensus. The earnings-call transcript provides additional management commentary on the company’s pipeline and financial outlook. Nektar Q2 2026 Earnings Call Transcript
- Positive Sentiment: Institutional ownership remains high at approximately 75.9%, while several funds—including AQR Capital Management, Two Seas Capital and Armistice Capital—recently increased their positions. The broader analyst consensus is still “Moderate Buy,” with an average price target well above the current trading level. Nektar institutional ownership and analyst ratings
- Neutral Sentiment: JPMorgan initiated coverage with a “Neutral” rating and a $65 price target. The target is below the recent share price, signaling limited near-term upside in JPMorgan’s view, although the rating is not an outright sell recommendation. JPMorgan initiates coverage of Nektar
- Neutral Sentiment: CEO Howard Robin and insider Jonathan Zalevsky sold shares to cover tax withholding obligations tied to vested equity awards. The transactions were relatively small compared with their remaining holdings, reducing their significance as a bearish signal. Nektar insider transactions
- Negative Sentiment: Revenue of $10.13 million fell slightly short of the $10.43 million estimate, while Nektar continues to report substantial losses and is expected to post approximately negative $8.60 in full-year EPS. HC Wainwright also issued a negative outlook for NKTR earnings, adding to concerns about ongoing cash burn and execution risk. HC Wainwright earnings outlook
Nektar Therapeutics Company Profile
Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.
Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.
Featured Articles
- Five stocks we like better than Nektar Therapeutics
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
